ArticleAnnals of clinical microbiology and antimicrobials2023
Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope.
Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Combating Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Ceftazidime-Avibactam/Aztreonam Combination for the Treatment of Carbapenem-resistant Klebsiella pneumoniae-induced Osteomyelitis: A Case Series with Review of Literature.Journal of orthopaedic case reports · 2026Article
- A Fivefold Maximum Drug-Likeness Strategy for Prioritizing Antibacterial Candidates AgainstPharmaceuticals (Basel, Switzerland) · 2026Article
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- Identification of Antibacterial Hits Associated with Penicillin-Binding Protein 2 inDrug design, development and therapy · 2026Article
- Treatment Options for Critically Ill Patients with Infections Caused by Metallo-Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Coexistence of carbapenem resistance and hypervirulence in clinical Klebsiella pneumoniae isolates: a molecular and phenotypic analysis.BMC infectious diseases · 2025Article
- Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused byAntibiotics (Basel, Switzerland) · 2025Article
- Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey.Antibiotics (Basel, Switzerland) · 2025Article
- Prevalence of New Delhi Metallo-β-lactamase (blaMolecular biology reports · 2025Article
- Targeted 'knock out' therapy with a combination antimicrobial regimen restores treatment options in the management of extensively drug-resistant carbapenemase-producing organisms.Journal of medical microbiology · 2025Article
- [In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of enterobacteriaceae andAnnals of burns and fire disasters · 2025Article
- Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.Scientific reports · 2025Article
- Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-ResistantInfection and drug resistance · 2025Article
- A Possible Tool for Guiding Therapeutic Approaches to Urinary Infections withAntibiotics (Basel, Switzerland) · 2024Article
- Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam againstMicrobiology spectrum · 2024Article
- Molecular and clinical epidemiology of carbapenem resistantThe Lancet regional health. Western Pacific · 2024Article
- It's uncomplicated: Prevention of urinary tract infections in an era of increasing antibiotic resistance.PLoS pathogens · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenemase-producing Enterobacterales (CPE) show rapid global dissemination and pose a significant therapeutic challenge. This study aimed to characterize carbapenemase-producing Klebsiella spp. and Escherichia coli (E. coli) phenotypically and genotypically and evaluate the effect of ceftazidime/ avibactam plus aztreonam combination.
methodsA total of 219 Klebsiella species and 390 E. coli strains were isolated from clinical samples, in which 80 Klebsiella spp. and 20 E coli isolates were resistant to tested carbapenems (imipenem, ertapenem, meropenem) by disk diffusion/broth dilution method and Vitek-2 compact system. MASTDISCS Combi Carba plus discs and real time PCR were used to determine type of carbapenemase phenotypically and genotypically, respectively. Interestingly, the synergistic effect between ceftazidime-avibactam (E-test) and aztreonam (disc) was tested against the CPE isolates.
resultsOut of the carbapenem-resistant isolates, 76.25% Klebsiella spp. isolates were extensively drug-resistant (XDR) while 18.75% were pan drug-resistant (PDR), and 5% were multidrug-resistant (MDR). Regarding E. coli, 5% were PDR, 20% were MDR and 75% were XDR. More than one carbapenemase gene was detected in 99% of the isolates. In comparison between MAST-Carba plus discs and PCR results, sensitivity and specificity were (85.42-97.92%) in Klebsiella spp., and (69.64-100%) in E. coli, respectively. Moreover, a strong association was detected between both test results among Klebsiella spp. (p < 0.001) and E. coli (p = 0.012) isolates. Finally, ceftazidime-avibactam and aztreonam combination showed a synergistic effect in 98.8% of Klebsiella spp. and 95% of E coli. All 16 PDR isolates showed synergy.
conclusionThis synergistic effect spots the light on new therapeutics for XDR and PDR CPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.